Replimune Group (NASDAQ:REPL) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPS

Replimune Group (NASDAQ:REPLGet Free Report) issued its earnings results on Thursday. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.12, Briefing.com reports.

Replimune Group Price Performance

Shares of NASDAQ:REPL opened at $7.76 on Friday. The company has a 50-day simple moving average of $8.05 and a 200-day simple moving average of $13.42. Replimune Group has a one year low of $5.89 and a one year high of $25.83. The company has a quick ratio of 12.76, a current ratio of 12.76 and a debt-to-equity ratio of 0.11.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. HC Wainwright lowered their target price on shares of Replimune Group from $50.00 to $48.00 and set a “buy” rating for the company in a research note on Monday, November 13th. Barclays decreased their price objective on shares of Replimune Group from $50.00 to $13.00 and set an “overweight” rating for the company in a research note on Wednesday, December 6th. Finally, Wedbush restated an “outperform” rating and issued a $52.00 price objective on shares of Replimune Group in a research note on Wednesday, November 8th.

View Our Latest Report on REPL

Insider Activity

In other news, insider Konstantinos Xynos sold 7,313 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $10.92, for a total value of $79,857.96. Following the completion of the sale, the insider now directly owns 112,714 shares of the company’s stock, valued at $1,230,836.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 20.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc raised its holdings in Replimune Group by 6.7% during the second quarter. Legal & General Group Plc now owns 8,324 shares of the company’s stock worth $146,000 after purchasing an additional 526 shares in the last quarter. Rhumbline Advisers increased its holdings in Replimune Group by 1.3% in the third quarter. Rhumbline Advisers now owns 70,544 shares of the company’s stock valued at $1,207,000 after buying an additional 939 shares in the last quarter. Alliancebernstein L.P. increased its holdings in Replimune Group by 3.3% in the fourth quarter. Alliancebernstein L.P. now owns 31,829 shares of the company’s stock valued at $866,000 after buying an additional 1,029 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in Replimune Group by 33.8% in the second quarter. Tower Research Capital LLC TRC now owns 8,690 shares of the company’s stock valued at $202,000 after buying an additional 2,197 shares in the last quarter. Finally, Principal Financial Group Inc. increased its holdings in Replimune Group by 21.2% in the first quarter. Principal Financial Group Inc. now owns 12,642 shares of the company’s stock valued at $223,000 after buying an additional 2,211 shares in the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

(Get Free Report)

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

See Also

Earnings History for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.